Many authors have reported ototoxicity resulting from treatment with Cisplatin, but the reason for specific toxicity of this drug to the inner ear as compared with other sensory structures is still not known. The authors study the effect of moderate dose Cisplatin therapy(50mg/m²) on hearing in forty-one patients with uterine cervical cancer. The following results were obtained ; 1) Age distribution was ranging from 20 to 50, and the mean age was 45.3 years. 2) Cumulative dose of Cisplatin was ranged from 50mg/m² to 300mg/m², and the mean dose was 135.4mg/m². 3) Hearing threshold was elevated after Cisplatin therapy at all testing frequency(0.5, 1, 2, 4, 6, 8KHz) with statistical significance. 4) The hearing threshold according to cumulative dose of Cisplatin was 16.82±4.47dB at 50mg/m² and 22.84±7.25dB above 250mg/m² showing significant evidence of elevation of hearing threshold as increasing of cumulative dose. 5) Threshold shift after treatment with Cisplatin were seen in 17 cases(43%), and their hearing threshold of pre-administration period was 17.2dB and of post-administration period was 22.4dB. 6) In the group of threshold shift, average hearing threshold was 17.32±4.17dB at 0.5KHz, and 33.86±9.44dB at 8KHz. Significant evidence was noted that hearing threshold increases in high frequencies especially above 4KHz. 7) In the group of threshold shift, average hearing threshold was 19.43±7.78dB at 50mg/m² of cumulative dose, and 31.64±17.49dB above 250mg/m². Significant evidence was noted that hearing threshold increases as cumulative dose increases. In summary, moderate dose of Cisplatin therapy could result in elevation of hearing threshold in 43% and this elevation of threshold is much higher as cumulative dose increases and in high frequencies especially above 4KHz.